Rezolute, Inc.
https://www.rezolutebio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Rezolute, Inc.
Rezolute Sees Big Opportunity For Oral Eye Disease Drug
The company reported positive topline data from a Phase II study testing RZ402 in patients with diabetic macular edema.
EMA Says Yes To PRIME Designations For Wet AMD & HAE Gene Therapies
Two gene therapies, from Molecular Therapeutics and Intellia Therapeutics respectively, are among the four new products the European Medicines Agency accepted onto it priority medicines scheme this month.
BIO Notebook: GSK’s Walmsley On M&A, Merck On How Falling Valuations Are Affecting Deals
On the first day of the BIO International Convention, our reporters hear from industry leaders about tough financing, when to go public, and why ‘there shouldn't be 700 listed biotechs in the US.’
BIO Notebook: GSK’s Walmsley On M&A, Merck On How Falling Valuations Are Affecting Deals
On the first day of the BIO International Convention, our reporters hear from industry leaders about tough financing, when to go public, and why ‘there shouldn't be 700 listed biotechs in the US.’
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Drug Discovery Technologies
- ADMET
-
Large Molecule
- Other Names / Subsidiaries
-
- AntriaBio, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice